Lucira Health Shares Up 341% After FDA Authorization as Company Seeks Strategic Partner

By Dia Gill

Lucira Health Inc. shares soared 340.7% to 62 cents Monday morning after the medical technology company announced it was seeking a strategic partner to help resume manufacturing of its recently approved Covid-19 & Flu test.

The company's stock more than doubled Friday after the Food and Drug Administration issued emergency authorization of its Covid-19 & Flu test, the first at-home test able to detect the flu, and the first test able to detect and differentiate between the flu and Covid-19.

Just days ahead of the FDA's authorization, Lucira filed for Chapter 11 bankruptcy. At the time, the company said it would continue its operations during the bankruptcy process, while seeking a sale of its business.

The company's stock is up 1.5% since the start of the year and down 88% since one year ago.

Write to Dia Gill at dia.gill@wsj.com

(END) Dow Jones Newswires

February 27, 2023 09:57 ET (14:57 GMT)

Lucira Health (NASDAQ:LHDX)
Historical Stock Chart
From Dec 2024 to Jan 2025